{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:29:29Z","timestamp":1793039369174,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.iac.2024.07.006","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T11:29:46Z","timestamp":1723807786000},"page":"673-692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biologics in Aspirin-Exacerbated Respiratory Disease and Allergic Bronchopulmonary Aspergillosis"],"prefix":"10.1016","volume":"44","author":[{"given":"Jenny","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.iac.2024.07.006_bib1","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-Exacerbated Respiratory Disease","volume":"379","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.iac.2024.07.006_bib2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: A 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.iac.2024.07.006_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/014556130708600715","article-title":"The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery","volume":"86","author":"Kim","year":"2007","journal-title":"Ear Nose Throat J"},{"issue":"6","key":"10.1016\/j.iac.2024.07.006_bib4","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1378\/chest.07-0713","article-title":"Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study","volume":"132","author":"Lee","year":"2007","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.iac.2024.07.006_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0091-6749(80)90143-8","article-title":"Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges","volume":"66","author":"Stevenson","year":"1980","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.07.006_bib6","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0091-6749(84)90361-0","article-title":"Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin","volume":"73","author":"Stevenson","year":"1984","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.07.006_bib7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2014.02.041","article-title":"Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study","volume":"134","author":"Swierczynska-Krepa","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.iac.2024.07.006_bib8","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/alr.21826","article-title":"Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations","volume":"6","author":"Levy","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"issue":"11","key":"10.1016\/j.iac.2024.07.006_bib9","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1398-9995.2006.01225.x","article-title":"Differentiation of chronic sinus diseases by measurement of inflammatory mediators","volume":"61","author":"Van Zele","year":"2006","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.iac.2024.07.006_bib10","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10209","key":"10.1016\/j.iac.2024.07.006_bib11","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.iac.2024.07.006_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.iac.2024.07.006_bib13","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.jaip.2022.05.016","article-title":"Pediatric-onset aspirin-exacerbated respiratory disease: Clinical characteristics, prevalence, and response to dupilumab","volume":"10","author":"Bensko","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2024.07.006_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1945892420961969","article-title":"Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease","volume":"35","author":"Mustafa","year":"2021","journal-title":"Am J Rhinol Allergy"},{"issue":"7","key":"10.1016\/j.iac.2024.07.006_bib15","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2024.07.006_bib16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anai.2021.11.020","article-title":"Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease","volume":"128","author":"Patel","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.iac.2024.07.006_bib17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.anai.2021.03.010","article-title":"Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease","volume":"126","author":"Mustafa","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.iac.2024.07.006_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaci.2022.09.012","article-title":"Mechanisms by which dupilumab normalizes eicosanoid metabolism and restores aspirin-tolerance in AERD: A hypothesis","volume":"151","author":"Picado","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2024.07.006_bib19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.iac.2024.07.006_bib20","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2024.07.006_bib21","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaip.2018.01.038","article-title":"A\u00a0retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease","volume":"6","author":"Tuttle","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2024.07.006_bib22","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jaip.2018.07.045","article-title":"Mepolizumab for the treatment of aspirin-exacerbated respiratory disease associated with coronary spasm","volume":"7","author":"Hagin","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2024.07.006_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13223-020-00423-3","article-title":"Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report","volume":"16","author":"Caruso","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2024.07.006_bib24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.anai.2019.06.012","article-title":"Mepolizumab utility in successful aspirin desensitization in aspirin-exacerbated respiratory disease in a refractory case","volume":"123","author":"Mahdavinia","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.iac.2024.07.006_bib25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.anai.2023.06.017","article-title":"Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth","volume":"131","author":"Supron","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.iac.2024.07.006_bib26","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jaip.2020.09.007","article-title":"Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: A case series","volume":"9","author":"Martin","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.iac.2024.07.006_bib27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.anai.2020.06.043","article-title":"Decreased nasal polyp eosinophils but increased mast cells in a patient with aspirin-exacerbated respiratory disease treated with reslizumab","volume":"125","author":"Staudacher","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.iac.2024.07.006_bib28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.iac.2024.07.006_bib29","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.iac.2024.07.006_bib30","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jaci.2023.03.014","article-title":"Omalizumab ameliorates extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease","volume":"151","author":"Hayashi","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2024.07.006_bib31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2500\/aap.2019.40.4241","article-title":"Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease","volume":"40","author":"Jean","year":"2019","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"10.1016\/j.iac.2024.07.006_bib32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaip.2015.01.012","article-title":"Omalizumab in the treatment of aspirin-exacerbated respiratory disease","volume":"3","author":"Bergmann","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2024.07.006_bib33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.iac.2024.07.006_bib34","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jaip.2016.12.013","article-title":"Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab","volume":"5","author":"Phillips-Angles","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2024.07.006_bib35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaci.2017.05.006","article-title":"Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: A single-center study","volume":"141","author":"Waldram","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2024.07.006_bib36","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2147\/JAA.S413064","article-title":"Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR","volume":"16","author":"Laidlaw","year":"2023","journal-title":"J\u00a0Asthma Allergy"},{"issue":"2","key":"10.1016\/j.iac.2024.07.006_bib37","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.iac.2024.07.006_bib38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.anai.2022.01.043","article-title":"Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: Efficacy, tolerability, and patient experience","volume":"128","author":"Mullur","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.iac.2024.07.006_bib39","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.jaip.2021.02.020","article-title":"Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Ralpha in a real-world setting","volume":"9","author":"Bavaro","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.iac.2024.07.006_bib40","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.anai.2022.07.023","article-title":"Type 2 biologics reduce cumulative steroid exposure in aspirin-exacerbated respiratory disease","volume":"129","author":"Ghiasi","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.07.006_bib41","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.07.006_bib42","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1164\/ajrccm.150.4.7921434","article-title":"Activated T\u00a0cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia","volume":"150","author":"Walker","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.iac.2024.07.006_bib43","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/cea.12354","article-title":"Pattern recognition pathways leading to a Th2 cytokine bias in allergic bronchopulmonary aspergillosis patients","volume":"45","author":"Becker","year":"2015","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.iac.2024.07.006_bib44","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1016\/j.ijid.2009.06.028","article-title":"Genetic variability of innate immunity impacts human susceptibility to fungal diseases","volume":"14","author":"Carvalho","year":"2010","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.iac.2024.07.006_bib45","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1086\/526500","article-title":"Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis","volume":"197","author":"Carvalho","year":"2008","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.iac.2024.07.006_bib46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13223-016-0152-y","article-title":"Genetic susceptibility to allergic bronchopulmonary aspergillosis in asthma: a genetic association study","volume":"12","author":"Overton","year":"2016","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.07.006_bib47","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00061-2024","article-title":"Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis\/mycoses","volume":"63","author":"Agarwal","year":"2024","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.iac.2024.07.006_bib48","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jaci.2020.08.029","article-title":"New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis\/mycosis and its validation","volume":"147","author":"Asano","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2024.07.006_bib49","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaip.2014.08.007","article-title":"Allergic bronchopulmonary aspergillosis","volume":"2","author":"Greenberger","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2024.07.006_bib50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/JAA.S156049","article-title":"Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"11","author":"Ashkenazi","year":"2018","journal-title":"J\u00a0Asthma Allergy"},{"issue":"3","key":"10.1016\/j.iac.2024.07.006_bib51","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaip.2022.12.012","article-title":"Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis","volume":"11","author":"Jin","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2024.07.006_bib52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2019.07.011","article-title":"Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis","volume":"19","author":"Koutsokera","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"2","key":"10.1016\/j.iac.2024.07.006_bib53","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ppul.23612","article-title":"Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients","volume":"52","author":"Nove-Josserand","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.iac.2024.07.006_bib54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.rmed.2017.11.007","article-title":"Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis","volume":"133","author":"Perisson","year":"2017","journal-title":"Respir Med"},{"issue":"9","key":"10.1016\/j.iac.2024.07.006_bib55","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1398-9995.2011.02599.x","article-title":"Allergic bronchopulmonary aspergillosis and omalizumab","volume":"66","author":"Tillie-Leblond","year":"2011","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.iac.2024.07.006_bib56","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","article-title":"Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis","volume":"3","author":"Voskamp","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2024.07.006_bib57","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jaip.2015.11.014","article-title":"Following total IgE concentration in patients with allergic bronchopulmonary aspergillosis on omalizumab","volume":"4","author":"Kelso","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2024.07.006_bib58","article-title":"Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?","author":"Korkmaz","year":"2022","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2024.07.006_bib59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejim.2021.12.026","article-title":"One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response","volume":"99","author":"Caminati","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"7","key":"10.1016\/j.iac.2024.07.006_bib60","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jaip.2020.03.023","article-title":"Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature","volume":"8","author":"Schleich","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.iac.2024.07.006_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1167","article-title":"Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis","volume":"11","author":"Alaga","year":"2023","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.iac.2024.07.006_bib62","article-title":"A\u00a0case of allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia successfully treated with benralizumab","volume":"32","author":"Tsubouchi","year":"2021","journal-title":"Respir Med Case Rep"},{"issue":"5","key":"10.1016\/j.iac.2024.07.006_bib63","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18176\/jiaci.0564","article-title":"Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Benralizumab in a Patient Who Did Not Respond to Omalizumab","volume":"30","author":"Bernal-Rubio","year":"2020","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.07.006_bib64","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.alit.2020.03.003","article-title":"Rapid clearance of mepolizumab-resistant bronchial mucus plugs in allergic bronchopulmonary aspergillosis with benralizumab treatment","volume":"69","author":"Tomomatsu","year":"2020","journal-title":"Allergol Int"},{"issue":"5","key":"10.1016\/j.iac.2024.07.006_bib65","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2022.12.049","article-title":"Allergic bronchopulmonary aspergillosis in identical twins: Effectiveness of dupilumab","volume":"11","author":"Lamothe","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2024.07.006_bib66","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13223-020-00454-w","article-title":"Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?","volume":"16","author":"Mummler","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.iac.2024.07.006_bib67","article-title":"Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: A case report","volume":"39","author":"Kai","year":"2022","journal-title":"Respir Med Case Rep"},{"issue":"7","key":"10.1016\/j.iac.2024.07.006_bib68","article-title":"A\u00a0Case of Allergic Bronchopulmonary Aspergillosis With Failure of Benralizumab and Response to Dupilumab","volume":"15","author":"Kotetsu","year":"2023","journal-title":"Cureus"},{"issue":"23","key":"10.1016\/j.iac.2024.07.006_bib69","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.12998\/wjcc.v9.i23.6922","article-title":"Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report","volume":"9","author":"Nishimura","year":"2021","journal-title":"World J Clin Cases"},{"issue":"2","key":"10.1016\/j.iac.2024.07.006_bib70","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaip.2019.11.031","article-title":"Dupilumab treatment for allergic bronchopulmonary aspergillosis: A case series","volume":"8","author":"Ramonell","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.iac.2024.07.006_bib71","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jaip.2023.05.026","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with tezepelumab","volume":"11","author":"Matsuno","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.iac.2024.07.006_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1147","article-title":"Tezepelumab treatment for allergic bronchopulmonary aspergillosis","volume":"11","author":"Ogata","year":"2023","journal-title":"Respirol Case Rep"},{"issue":"4","key":"10.1016\/j.iac.2024.07.006_bib73","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jaip.2017.01.013","article-title":"Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis","volume":"5","author":"Altman","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.iac.2024.07.006_bib74","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.arbres.2021.12.005","article-title":"Successful Long-Term Treatment Combining Omalizumab and Anti-IL-5 Biologics in Allergic Bronchopulmonary Aspergillosis","volume":"58","author":"Laorden","year":"2022","journal-title":"Arch Bronconeumol"},{"issue":"3","key":"10.1016\/j.iac.2024.07.006_bib75","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.alit.2018.12.008","article-title":"Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab","volume":"68","author":"Soeda","year":"2019","journal-title":"Allergol Int"},{"issue":"5","key":"10.1016\/j.iac.2024.07.006_bib76","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jaip.2018.11.024","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with benralizumab","volume":"7","author":"Soeda","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.iac.2024.07.006_bib77","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omaa029","article-title":"Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis","volume":"2021","author":"Ali","year":"2021","journal-title":"Oxf Med Case Reports"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:39:46Z","timestamp":1728391186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856124000559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0889856124000559"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2024.07.006","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in Aspirin-Exacerbated Respiratory Disease and Allergic Bronchopulmonary Aspergillosis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2024.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}